Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines

Daniel A. Pollyea, Dale Bixby, Alexander Perl, Vijaya Raj Bhatt, Jessica K. Altman, Frederick R. Appelbaum, Marcos De Lima, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Jadee Neff, Reza Nejati, Rebecca OlinMary Elizabeth Percival, Thomas Prebet, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi-Kashani, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Kendra Sweet, Pankit Vachhani, Matthew Wieduwilt, Kristina M. Gregory, Ndiya Ogba, Martin S. Tallman

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.

Original languageEnglish (US)
Pages (from-to)16-27
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume19
Issue number1
DOIs
StatePublished - Jan 2021

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines'. Together they form a unique fingerprint.

Cite this